Elan wins shareholder approval to complete Perrigo sale
DUBLIN (Reuters) - Ireland's Elan won approval from shareholders on Monday to complete the sale of the company to U.S. drugmaker Perrigo, clearing the way for the deal to be completed by the end of the year.
Perrigo agreed to buy the Dublin-based group for $8.6 billion in July in a deal that will hand it tax savings from being domiciled in Ireland and royalties from blockbuster multiple sclerosis treatment Tysabri.
The deal ended a bitter takeover battle in which Elan rejected three lower bids from U.S. investment firm Royalty Pharma.
(Reporting by Padraic Halpin; editing by Keiron Henderson)
- China anxiety knocks shares, oil
- NATO countries have begun arms deliveries to Ukraine: defense minister |
- Alibaba worried about Facebook IPO as considered Nasdaq versus NYSE
- North Korea sentences U.S. citizen Matthew Miller to six years hard labor |
- U.S. sees Middle East help fighting IS, Britain cautious after beheading
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video